Amyotrophic lateral sclerosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 17: Line 17:


==[[Amyotrophic lateral sclerosis overview|Overview]]==
==[[Amyotrophic lateral sclerosis overview|Overview]]==
Amyotrophic Lateral Sclerosis is a chronic progressive neurological disease that affects both upper and lower motor neurons. It presents with muscle spasms, fasciculation, weakness and which could ultimately lead to muscles paralysis. ALS is diagnosed clinically, however additional testing with electromyography to confirm muscle denervation. Laboratory tests might be required to rule out other reversible causes of weakness. ALS has a poor prognosis with death usually due to respiratory complications with a median survival of 3-5 years. ALS is managed by a multidisciplinary care setting with fewer disease modifying agents to date.


==[[Amyotrophic lateral sclerosis historical perspective|Historical Perspective]]==
==[[Amyotrophic lateral sclerosis historical perspective|Historical Perspective]]==
Amyotrophic Lateral Sclerosis was first described by French neurologist Jean-Martin Charcot in his Tuesday lectures in late 1860 and then a publication in 1874. He is also known as the ''' Father of Amyotrophic Lateral Sclerosis''' because of his devotion to the disease. He complied 50 years of previous work on muscle weakness. He was the first scientist to link the disease to its specific pathology.
<ref name="pmid26515617">{{cite journal| author=Katz JS, Dimachkie MM, Barohn RJ| title=Amyotrophic Lateral Sclerosis: A Historical Perspective. | journal=Neurol Clin | year= 2015 | volume= 33 | issue= 4 | pages= 727-34 | pmid=26515617 | doi=10.1016/j.ncl.2015.07.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26515617  }} </ref>


==[[Amyotrophic lateral sclerosis classification|Classification]]==
==[[Amyotrophic lateral sclerosis classification|Classification]]==
Line 46: Line 49:


==Related Chapters==
==Related Chapters==
* [[Muscular Dystrophy Association]]
 
* [[ALS Association]]
*[[Muscular Dystrophy Association]]
* [[ALS Therapy Development Institute]]
*[[ALS Association]]
*[[ALS Therapy Development Institute]]


==References==
==References==

Latest revision as of 11:32, 2 July 2021

Amyotrophic lateral sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Amyotrophic lateral sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amyotrophic lateral sclerosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amyotrophic lateral sclerosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amyotrophic lateral sclerosis

CDC on Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis in the news

Blogs on Amyotrophic lateral sclerosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Amyotrophic lateral sclerosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.

Amyotrophic lateral sclerosis
Stephen Hawking, a physicist who has ALS.
ICD-10 G12.2
ICD-9 335.20
OMIM 105400
DiseasesDB 29148
MedlinePlus 000688
MeSH D000690

Overview

Amyotrophic Lateral Sclerosis is a chronic progressive neurological disease that affects both upper and lower motor neurons. It presents with muscle spasms, fasciculation, weakness and which could ultimately lead to muscles paralysis. ALS is diagnosed clinically, however additional testing with electromyography to confirm muscle denervation. Laboratory tests might be required to rule out other reversible causes of weakness. ALS has a poor prognosis with death usually due to respiratory complications with a median survival of 3-5 years. ALS is managed by a multidisciplinary care setting with fewer disease modifying agents to date.

Historical Perspective

Amyotrophic Lateral Sclerosis was first described by French neurologist Jean-Martin Charcot in his Tuesday lectures in late 1860 and then a publication in 1874. He is also known as the Father of Amyotrophic Lateral Sclerosis because of his devotion to the disease. He complied 50 years of previous work on muscle weakness. He was the first scientist to link the disease to its specific pathology. [1]

Classification

Pathophysiology

Causes

Differentiating Amyotrophic lateral sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Evaluation | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

References

  1. Katz JS, Dimachkie MM, Barohn RJ (2015). "Amyotrophic Lateral Sclerosis: A Historical Perspective". Neurol Clin. 33 (4): 727–34. doi:10.1016/j.ncl.2015.07.013. PMID 26515617.

Template:Diseases of the nervous system

Template:WS Template:WH